0001079973-22-001411.txt : 20221110 0001079973-22-001411.hdr.sgml : 20221110 20221110161912 ACCESSION NUMBER: 0001079973-22-001411 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20221108 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20221110 DATE AS OF CHANGE: 20221110 FILER: COMPANY DATA: COMPANY CONFORMED NAME: OPGEN INC CENTRAL INDEX KEY: 0001293818 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 061614015 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37367 FILM NUMBER: 221377523 BUSINESS ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-869-9683 MAIL ADDRESS: STREET 1: 9717 KEY WEST AVENUE STREET 2: SUITE 100 CITY: ROCKVILLE STATE: MD ZIP: 20850 8-K 1 opgen_8k-110922.htm FORM 8-K
0001293818 false 0001293818 2022-11-08 2022-11-08 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

_________________

FORM 8-K

_________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

  November 8, 2022
Date of Report (date of earliest event reported)

_________________

OpGen, Inc.

(Exact name of Registrant as specified in its charter)

_________________

Delaware

(State or other jurisdiction of incorporation or organization)

  

001-37367

(Commission

File Number)

  

06-1614015

(I.R.S. Employer
Identification Number)

9717 Key West Ave, Suite 100
Rockville, MD 20850
(Address of principal executive offices)(Zip code)

(301) 869-9683
(Registrant's telephone number, including area code)

Not Applicable
(Former name or former address, if changed since last report)

_________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class Trading Symbol(s) Name of each exchange on which registered
Common Stock OPGN The Nasdaq Capital Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 
 
 

Item 2.02 Results of Operations and Financial Condition

 

On November 10, 2022, OpGen, Inc. (the “Company”) issued a press release announcing its financial results for the third quarter ended September 30, 2022. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

 

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On November 8, 2022, the Board of Directors of the Company (the “Board”) elected Yvonne Schlaeppi as a member of its Board of Directors. The Board also confirmed that Ms. Schlaeppi is an independent director under applicable standards, including Nasdaq corporate governance standards. Her term as a director began on November 8, 2022.

 

Since 2011, Ms. Schlaeppi has served as a Managing Partner of Stratevise LLC, an international strategic advisory firm that she cofounded. From 2016 through its going private in 2019, Ms. Schlaeppi served on the board of directors of Stallergenes Greer plc, a pharmaceutical company traded on the Euronext Paris exchange. From 2014 to 2015, Ms. Schlaeppi served on the boards of directors of allergy immunotherapy companies, Ares Allergy Holdings Inc. and Greer Laboratories, Inc. Since 2018, Ms. Schlaeppi has been a director of AstroNova, Inc., a Nasdaq-listed industrial company, which applies data visualization technologies to its hardware and software products for the aerospace and defense, packaging and product identification, and electronic signal data test and measurement sectors, as well as Chair of its Nominating and Governance Committee and a member of its Audit Committee. Since 2015, Ms. Schlaeppi has been a member of the External Advisory Council to the Channing Division of Network Medicine of Brigham and Women’s Hospital in Boston. Ms. Schlaeppi has been recognized as Directorship Certified by the National Association of Corporate Directors (“NACD”) in 2022 and, from 2017 to 2022, has been recognized annually as a Board Leadership Fellow by the NACD. Prior to founding Stratevise, Ms. Schlaeppi served as General Counsel at Global Enterprise Technologies, Passport & ID, a high-security document printing solutions provider and systems integrator from 2007 to 2011 and as Executive Vice President, General Counsel and Corporate IP Officer at Organon BioSciences, a global pharmaceutical, animal health and biotech group based in the Netherlands, from 2006 until its sale in 2007. From 1999 to 2006, Ms. Schlaeppi was a partner at the Boston-based law firm of Palmer & Dodge LLP, where she served as Chairperson of that firm’s International Practice Group. From 1995 to 1998 Ms. Schlaeppi served in senior positions at Johnson Controls, Inc., a NYSE-listed diversified industrial company, including as General Counsel Europe. The Company believes that Ms. Schlaeppi’s extensive experience in life sciences, as well as international business and corporate governance, qualify her to serve on the Company’s Board of Directors.

 

In light of her prior experience with audit-, risk- and governance-related matters, the Board also appointed Ms. Schlaeppi to the Company’s Audit Committee.

 

The Company entered into an indemnification agreement with Ms. Schlaeppi in the form previously approved by the Board.

 

Item 9.01 —  Financial Statements and Exhibits.

(d) Exhibits

 

10.1 Form of Indemnification Agreement between the Registrant and each of its directors and executive officers (incorporated by reference to Exhibit 10.2 of Form S-1, File No. 333-202478, filed on March 3, 2015).
99.1 Press release dated November 10, 2022.
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

The information included in Item 2.02 herein and in Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (“Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

 

 

 
 
 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

             
Date: November 10, 2022   OpGen, Inc.
       
    By:  

/s/ Albert Weber

        Name:   Albert Weber
        Title:   Chief Financial Officer

 

 EX-99.1 2 ex99x1.htm EXHIBIT 99.1

Exhibit 99.1

 

 

 

OpGen Reports Third Quarter 2022 Financial Results and Provides Business Update

 

·Completes first two commercial customer installations for Acuitas AMR Gene Panel
·OpGen subsidiary, Curetis, signed collaboration agreement with BioVersys AG and R&D collaboration agreement with FIND for the Unyvero A30 RQ platform
·Elects Yvonne Schlaeppi as new, independent non-executive director to the board
·Management conference call scheduled for November 10, 2022, at 4:30 p.m. EST

 

ROCKVILLE, MD., November 10, 2022 (GLOBE NEWSWIRE) – OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease, reported its third quarter 2022 financial and operating results. Management will host an investor call to discuss quarterly results and provide a business update.

 

Oliver Schacht, President & CEO of OpGen, commented, “During the third quarter we reached multiple agreements and entered into collaborations with various partners. These include our research collaboration agreement with the Belgian National Reference Center (BNRC), an R&D collaboration with FIND, our second commercial installation of the Acuitas AMR Gene Panel, a new commercial contract for Unyvero in the U.S., and a collaboration agreement with BioVersys. We are seeing progress on both the R&D and commercial fronts and look forward to the upcoming progress.”

 

Mr. Schacht continued, “As we proceed through 2022 and move into the calendar year of 2023, we have several upcoming catalysts and milestones to look forward to, including our UTI clinical trial data read-out and anticipated subsequent FDA submission, proceeds from the FIND collaboration as well as its potential future extension and expansion, and several potential new commercial contracts with U.S. customers across Unyvero and Acuitas products. We look forward to announcing these potential milestones as we continue to focus on building shareholder value.”

 

Third Quarter 2022 Financial Results of OpGen, Inc.

 

·Total revenue for the third quarter of 2022 was approximately $0.4 million, compared with approximately $1.2 million in the third quarter of 2021. Total revenue for the nine months ended September 30, 2022 was approximately $1.9 million, compared with approximately $2.9 million for the nine months ended September 30, 2021.
·Operating expenses for the third quarter of 2022 were approximately $14.0 million, compared with approximately $6.3 million in the third quarter of 2021. Operating expenses for the nine months ended September 30, 2022 were approximately $26.5 million, compared with approximately $20.4 million for the nine months ended September 30, 2021.
·The net loss available to common stockholders for the third quarter of 2022 was approximately $14.1 million, or $0.30 per share, compared with approximately $6.1 million, or $0.16 per share, in the third quarter of 2021. Net loss for the nine months ended September 30, 2022 was approximately $26.7 million, compared with approximately $28.0 million for the nine months ended September 30, 2021.
·Cash and cash equivalents were approximately $10.3 million as of September 30, 2022, compared with $36.1 million as of December 31, 2021.

 

 

 
 

In the third quarter and year to date, the Company reached the following key milestones:

·OpGen subsidiary, Ares Genetics, signed a research collaboration agreement with the Belgian National Reference Center (BNRC) for invasive Streptococcus pneumoniae at the University Hospital Leuven.
·OpGen subsidiary, Ares Genetics, launched the ARESiss isolate sequencing service in the U.S.
·OpGen completed enrollment of over 1,800 patient samples for the prospective multicenter clinical trial in the U.S. for the Unyvero UTI Panel on the Unyvero A50 platform.
·OpGen subsidiary, Curetis, signed an R&D collaboration agreement with FIND for the Unyvero A30 RQ platform.
·OpGen signed an additional commercial contract for the Acuitas AMR Gene Panel and initiated the first two customer sites in the U.S. with installations, trainings and delivery of Acuitas kits.
·OpGen subsidiary, Curetis, signed a collaboration agreement with BioVersys AG from Switzerland to use the Unyvero platform in BioVersys’ upcoming Phase II clinical trial.
·OpGen received an update from Beijing Clear Biotech’s regulatory advisors about feedback from China’s NMPA regarding the Unyvero A50 pneumonia product and the need to resubmit our filing under a new electronic filing regime that NMPA has recently implemented.
·Nasdaq granted OpGen an extension until February 27, 2023 to meet Nasdaq’s minimum bid price requirement.
·This week, OpGen's board elected Yvonne Schlaeppi as a new, independent non-executive member of the Company’s board of directors. Ms. Schlaeppi brings legal, governance, life sciences and international experience to the board.  Since 2011, Ms. Schlaeppi has served as a Managing Partner of Stratevise LLC, an international strategic advisory firm that she co-founded. Prior to founding Stratevise, Ms. Schlaeppi served as General Counsel at Global Enterprise Technologies, Passport & ID, a high-security document printing solutions provider and systems integrator, from 2007 to 2011, and as Executive Vice President, General Counsel and Corporate IP Officer at Organon BioSciences, a global pharmaceutical, animal health and biotech group based in the Netherlands, from 2006 until its sale in 2007. Prior to that, Ms. Schlaeppi was a partner at the Boston-based law firm of Palmer & Dodge LLP, where she served as Chairperson of that firm’s International Practice Group. Ms. Schlaeppi has been recognized by the National Association of Corporate Directors as Directorship Certified®, has served on the board of directors of several public companies and currently is a member of the board of AstroNova, Inc.

 

 
 

In terms of guidance, the Company anticipates:

·The unblinding of data from the Unyvero UTI trial around year-end and subsequent FDA submission in 2023;
·To enter into new commercial contracts in the coming months across Unyvero and Acuitas products, which contracts could have the potential to drive revenue growth for 2023;
·Further developing ARES services and progressing strategic collaborations and partnerships with U.S. key accounts and leading organizations; and
·Overall, 2022 revenue in a range of approximately $2.5 to $3 million from products and services as well as collaboration business globally.
·OpGen will be holding a special meeting of stockholders on November 30, 2022 to vote on the proposal for a potential reverse stock split.
·The Company will continue to explore additional strategic and tactical equity and debt financing opportunities as well as potential strategic alternative options throughout the remainder of the year and into 2023 to possibly further strengthen its cash position.

 

Conference Call Information

OpGen’s management will host a conference call today, November 10, at 4:30 p.m. EST, to discuss the third quarter financial results and business activities, as well as answer analyst questions.

 

Conference Call Details  
U.S. Dial-in Number: 1-877-704-4453
International Dial-in Number: 1-201-389-0920
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1569725&tp_key=91a31a2b1f
Conference ID: 13732787

 

Following the conclusion of the conference call, a replay will be available through November 24th, 2022.

The live, listen-only webcast of the conference call may also be accessed by visiting the Investors section of the Company’s website at www.opgen.com.

 

A replay of the webcast will be available following the conclusion of the call and will be archived on the Company’s website for 90 days. Replay access information is below:

 

Replay Details

U.S. Dial-in Number: 1-844-512-2921
International Dial-in Number: 1-412-317-6671
Replay PIN: 13732787

About OpGen, Inc.

OpGen, Inc. (Rockville, MD, U.S.A.) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with our subsidiaries, Curetis GmbH and Ares Genetics GmbH, we are developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen’s current product portfolio includes Unyvero, Acuitas AMR Gene Panel, and the ARES Technology Platform including ARESdb, NGS technology and AI-powered bioinformatics solutions for AMR surveillance, outbreak analysis, and antibiotic response prediction including ARESiss, ARESid, and AREScloud, as well as the Curetis CE-IVD-marked PCR-based SARS-CoV-2 test kit.

 

For more information, please visit www.opgen.com.

 
 

Forward-Looking Statements

This press release includes statements regarding OpGen’s third quarter 2022 financial results and the current business of OpGen. These statements and other statements regarding OpGen’s future plans and goals constitute "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that are often difficult to predict, are beyond our control, and which may cause results to differ materially from expectations. Factors that could cause our results to differ materially from those described include, but are not limited to, the success of our commercialization efforts, our ability to successfully, timely and cost-effectively develop, seek and obtain regulatory clearance for and commercialize our product and services offerings, the rate of adoption of our products and services by hospitals and other healthcare providers, the fact that we may not effectively use proceeds from recent financings, the continued realization of expected benefits of our business combination transaction with Curetis GmbH, the continued impact of COVID-19 on the Company’s operations, financial results, and commercialization efforts as well as on capital markets and general economic conditions, our ability to satisfy debt obligations under our loan with the European Investment Bank, the effect of the military action in Russia and Ukraine on our distributors, collaborators and service providers, our liquidity and working capital requirements, the effect on our business of existing and new regulatory requirements, and other economic and competitive factors. For a discussion of the most significant risks and uncertainties associated with OpGen's business, please review our filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which are based on our expectations as of the date of this press release and speak only as of the date of this press release. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

 

 
 

 

 

 

 

OpGen, Inc.
Consolidated Balance Sheets
(unaudited)
         
    September 30, 2022    December 31, 2021 
Assets          
Current assets          
Cash and cash equivalents  $10,275,654   $36,080,392 
Accounts receivable, net   665,313    1,172,396 
Inventory, net   771,864    1,239,456 
Prepaid expenses and other current assets   1,678,729    1,250,331 
Total current assets   13,391,560    39,742,575 
Property and equipment, net   3,054,990    4,011,748 
Finance lease right-of-use assets, net   4,347    90,467 
Operating lease right-of-use assets   1,472,934    1,814,396 
Goodwill   —      7,453,007 
Intangible assets, net   12,001,036    14,530,209 
Strategic inventory   2,614,805    3,472,337 
Other noncurrent assets   419,495    551,794 
Total assets  $32,959,167   $71,666,533 
Liabilities and Stockholders’ Equity          
Current liabilities          
Accounts payable  $682,592   $1,307,081 
Accrued compensation and benefits   1,391,145    1,621,788 
Accrued liabilities   1,046,865    1,965,845 
Deferred revenue   194,960    —   
Short-term notes payable   8,342,715    14,519,113 
Short-term finance lease liabilities   6,748    43,150 
Short-term operating lease liabilities   346,629    459,792 
Total current liabilities   12,011,654    19,916,769 
Note payable   4,108,421    7,176,251 
Derivative liabilities   146,207    228,589 
Long-term finance lease liabilities   1,121    3,644 
Long-term operating lease liabilities   2,631,957    2,977,402 
Other long term liabilities   121,496    146,798 
Total liabilities   19,020,856    30,449,453 
Stockholders' equity          
Preferred stock, $0.01 par value; 10,000,000 shares authorized; none issued and outstanding at September 30, 2022 and December 31, 2021, respectively   —      —   
Common stock, $0.01 par value; 100,000,000 shares authorized; 48,338,500 and 46,450,250 shares issued and outstanding at September 30, 2022 and  December 31, 2021, respectively   483,386    464,503 
Additional paid-in capital   277,406,700    275,708,490 
Accumulated deficit   (262,289,652)   (235,541,539)
Accumulated other comprehensive (loss)/income   (1,662,123)   585,626 
Total stockholders’ equity   13,938,311    41,217,080 
Total liabilities and stockholders’ equity  $32,959,167   $71,666,533 

 

 

 

 
 

 

 

OpGen, Inc.
Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
                 
   Three Months Ended September 30,   Nine Months Ended September 30, 
   2022   2021   2022   2021 
Revenue                
Product sales  $359,112   $643,887   $1,614,435   $1,479,270 
Laboratory services   31,016    192,753    94,515    643,602 
Collaboration revenue   58,585    402,492    176,713    757,591 
Total revenue   448,713    1,239,132    1,885,663    2,880,463 
Operating expenses                    
Cost of products sold   1,886,191    648,298    2,824,577    1,544,932 
Cost of services   17,239    203,314    63,450    446,232 
Research and development, net   2,031,113    2,382,303    6,621,310    8,055,384 
General and administrative   2,020,452    2,088,226    6,779,773    7,444,138 
Sales and marketing   1,031,496    1,003,577    3,252,277    2,705,378 
Impairment of right-of-use asset   —      —      —      170,714 
Goodwill impairment charge   6,975,520    —      6,975,520    —   
Total operating expenses   13,962,011    6,325,718    26,516,907    20,366,778 
Operating loss   (13,513,298)   (5,086,586)   (24,631,244)   (17,486,315)
Other expense                    
Gain on extinguishment of debt   —      —      —      259,353 
Warrant inducement expense   —      —      —      (7,755,541)
Interest and other income, net   11,174    31,844    28,147    41,471 
Interest expense   (569,306)   (1,222,867)   (2,618,799)   (3,586,018)
Foreign currency transaction gains   (51,547)   229,074    419,160    655,774 
Change in fair value of derivative financial instruments   18,995    (8,161)   54,623    (122,572)
Total other expense   (590,684)   (970,110)   (2,116,869)   (10,507,533)
Loss before income taxes   (14,103,982)   (6,056,696)   (26,748,113)   (27,993,848)
Provision for income taxes   —      —      —      —   
Net loss  $(14,103,982)  $(6,056,696)  $(26,748,113)  $(27,993,848)
Net loss available to common stockholders  $(14,103,982)  $(6,056,696)  $(26,748,113)  $(27,993,848)
Basic and diluted net loss per share attributable to common stockholders  $(0.30)  $(0.16)  $(0.57)  $(0.79)
Weighted average shares outstanding - basic and diluted   47,656,972    38,270,250    46,915,880    35,373,397 
Net loss  $(14,103,982)  $(6,056,696)  $(26,748,113)  $(27,993,848)
Other comprehensive loss - foreign currency translation   (536,758)   (597,527)   (2,247,749)   (1,146,355)
Comprehensive loss  $(14,640,740)  $(6,654,223)  $(28,995,862)  $(29,140,203)

 

 

 

 

 

 

 

 

 GRAPHIC 3 image_001.jpg GRAPHIC begin 644 image_001.jpg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end EX-101.SCH 4 opgn-20221108.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 opgn-20221108_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 opgn-20221108_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.22.2.2
Cover
Nov. 08, 2022
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 08, 2022
Entity File Number 001-37367
Entity Registrant Name OpGen, Inc.
Entity Central Index Key 0001293818
Entity Tax Identification Number 06-1614015
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 9717 Key West Ave
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Rockville
Entity Address, State or Province MD
Entity Address, Postal Zip Code 20850
City Area Code 301
Local Phone Number 869-9683
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol OPGN
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 opgen_8k-110922_htm.xml IDEA: XBRL DOCUMENT 0001293818 2022-11-08 2022-11-08 iso4217:USD shares iso4217:USD shares 0001293818 false 8-K 2022-11-08 OpGen, Inc. DE 001-37367 06-1614015 9717 Key West Ave Suite 100 Rockville MD 20850 301 869-9683 false false false false Common Stock OPGN NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.2.2 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://opgen.com/role/Cover Cover Cover 1 false false All Reports Book All Reports opgen_8k-110922.htm ex99x1.htm opgn-20221108.xsd opgn-20221108_lab.xml opgn-20221108_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "opgen_8k-110922.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "opgen_8k-110922.htm" ] }, "labelLink": { "local": [ "opgn-20221108_lab.xml" ] }, "presentationLink": { "local": [ "opgn-20221108_pre.xml" ] }, "schema": { "local": [ "opgn-20221108.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 23, "memberCustom": 0, "memberStandard": 0, "nsprefix": "OPGN", "nsuri": "http://opgen.com/20221108", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "opgen_8k-110922.htm", "contextRef": "From2022-11-08to2022-11-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://opgen.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "p", "body", "html" ], "baseRef": "opgen_8k-110922.htm", "contextRef": "From2022-11-08to2022-11-08", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://opgen.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" } }, "version": "2.1" } ZIP 15 0001079973-22-001411-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001079973-22-001411-xbrl.zip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end